EFFECT ON VIRAL LOAD OF DELAYED PHENOTYPING VS IMMEDIATE PHENOTYPING

Rockefeller University, New York NY

Investigators

Linked publications & trials

Abstract

The primary objective is to assess the clinical advantage of the "Antivirogram" as part of the treatment strategy compared with standard practice therapy on the number of subjects attaining a virologic end point during the 16-week evaluation period. Secondary objectives include assessment of the clinical advantage of the "Antivirogram" as part of the treatment strategy compared with standard practice therapy on: 1) The proportion of subjects with viral load levels below the limit of assay quantitation at 16 weeks as measured by HIV-1 RNA PCR; 2) Change in viral load as assessed by average area under the curve minus baseline (AAUCMB) ; and 3) The degree and duration of immunologic change (CD$ count, CD4%) as assessed by AAUCMB.